隶属于 ningbo kaiming investment management lp
相关临床试验
79
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2003
进行中（未招募）
4
5.1%
已完成
17
21.5%
尚未招募
6
7.6%
招募中
17
21.5%
暂停
1
1.3%
终止
1
1.3%
Unknown
33
41.8%
暂无批准数据
- Xcovery Holdings has partnered with EVERSANA to support the U.S. commercial launch of Ensacove (ensartinib), a next-generation ALK inhibitor for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer. - The drug is indicated for treatment-naïve patients who have not previously received an ALK inhibitor and is now available in the United States following FDA approval. - EVERSANA will provide comprehensive end-to-end commercialization services including market access, commercial and medical teams to broaden patient access across the U.S. - The partnership represents a strategic move to advance precision oncology and ensure patients and healthcare providers have adequate support for this targeted therapy.
- C4 Therapeutics plans to initiate the Phase 2 MOMENTUM trial of cemsidomide in Q1 2026, targeting fourth-line or later relapsed/refractory multiple myeloma patients with a recommended dose of 100 µg. - Phase 1 data demonstrated compelling anti-myeloma activity with 53% overall response rate at the 100 µg dose level in heavily pretreated patients, supporting cemsidomide's potential best-in-class profile. - The company has developed a regulatory pathway for two potential accelerated approvals and plans to submit a new drug application by year-end 2028. - C4 Therapeutics has secured cash runway through end of 2028 and is expanding its discovery strategy to target inflammation and neurodegenerative diseases.
- EyePoint Pharmaceuticals announced a $150 million public offering to fund clinical development of DURAVYU for wet age-related macular degeneration and diabetic macular edema. - DURAVYU combines vorolanib, a selective tyrosine kinase inhibitor, with the company's bioerodible Durasert E technology for sustained delivery treatment. - The investigational therapy is currently in Phase 3 pivotal trials for wet AMD with data expected in mid-2026, while Phase 3 trials for diabetic macular edema are planned to begin in Q1 2026. - The funding will also support earlier-stage pipeline development and general corporate purposes as the company advances its retinal disease portfolio.
- Angel Pharmaceuticals received IND approval from China's NMPA to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis treatment. - The randomized, double-blinded, placebo-controlled trial will evaluate multiple dosing regimens over 12 weeks, with patient enrollment expected to begin in Q3 2025. - Soquelitinib is an investigational oral ITK inhibitor developed by Corvus Pharmaceuticals, representing a novel immunotherapy approach for immune diseases. - Phase 1b data is anticipated in 2026, while Corvus continues parallel development in the U.S. with plans for a Phase 2 trial by year-end.
- C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma. - CFT1946, targeting BRAF V600 mutations in solid tumors, is progressing through Phase 1, with data readouts anticipated in the second half of 2025. - Phase 1 data from CFT8919, aimed at EGFR L858R-mutated non-small cell lung cancer, will inform future development plans outside of China. - C4 Therapeutics' cash runway is projected to fund operations into 2027, supporting ongoing research and clinical programs.
- EyePoint Pharmaceuticals reported positive interim results from its Phase 2 VERONA trial of DURAVYU for diabetic macular edema (DME). - DURAVYU 2.7mg demonstrated an 8.9 letter improvement in BCVA and a 68 micron reduction in CST at 16 weeks compared to baseline. - The study showed a favorable safety profile with no DURAVYU-related ocular or systemic serious adverse events reported. - Full topline data from the VERONA trial is anticipated in the first quarter of 2025, potentially leading to pivotal trials.
